Drug Trial Radar · NCT07290569
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Dec 3, 2025
Primary completion
Oct 21, 2026
Study completion Dec 2028
Sponsor
- Lead sponsor
- Oruka Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Conditions
- Plaque Psoriasis
Interventions
ORKA-001Drug
ORKA-001 administered by subcutaneous (SC) injection
PlaceboOther
Placebo administered by subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16Time frame: Week 16
Locations
36 sites in 4 countries. Site status is shown where the registry gives one.
Oruka Therapeutics Investigative Site
Phoenix, Arizona
Oruka Therapeutics Investigative Site
North Little Rock, Arkansas
Oruka Therapeutics Investigative Site
Los Angeles, California
Oruka Therapeutics Investigative Site
Los Angeles, California
Oruka Therapeutics Investigative Site
San Diego, California
Oruka Therapeutics Investigative Site
Miami, Florida
Oruka Therapeutics Investigative Site
Rolling Meadows, Illinois
Oruka Therapeutics Investigative Site
Plainfield, Indiana
Oruka Therapeutics Investigative Site
Rockville, Maryland
Oruka Therapeutics Investigative Site
Kew Gardens, New York
Oruka Therapeutics Investigative Site
Chapel Hill, North Carolina
Oruka Therapeutics Investigative Site
Cleveland, Ohio
Oruka Therapeutics Investigative Site
Mason, Ohio
Oruka Therapeutics Investigative Site
Portland, Oregon
Oruka Therapeutics Investigative Site
Portland, Oregon
Oruka Therapeutics Investigative Site
Philadelphia, Pennsylvania
Oruka Therapeutics Investigative Site
Frisco, Texas
Oruka Therapeutics Investigative Site
Houston, Texas
Oruka Therapeutics Investigative Site
Webster, Texas
Oruka Therapeutics Investigative Site
Norfolk, Virginia
Oruka Therapeutics Investigative Site
Surrey, British Columbia, Canada
Oruka Therapeutics Investigative Site
Surrey, British Columbia, Canada
Oruka Therapeutics Investigative Site
Fredericton, New Brunswick, Canada
Oruka Therapeutics Investigative Site
Ajax, Ontario, Canada
Oruka Therapeutics Investigative Site
Markham, Ontario, Canada
Oruka Therapeutics Investigative Site
Peterborough, Ontario, Canada
Oruka Therapeutics Investigative Site
Montreal, Quebec, Canada
Oruka Therapeutics Investigative Site
Québec, Quebec, Canada
Oruka Therapeutics Investigative Site
Heidelberg, Baden-Wuerrtemberg, Germany
Oruka Therapeutics Investigative Site
Frankfurt am Main, Hesse, Germany
Oruka Therapeutics Investigative Site
Bad Bentheim, Lower Saxony, Germany
Oruka Therapeutics Investigative Site
Kiel, Schleswig-Holstein, Germany
Oruka Therapeutics Investigative Site
Badalona, Barcelona, Spain
Oruka Therapeutics Investigative Site
Barcelona, Barcelona, Spain
Oruka Therapeutics Investigative Site
Madrid, Madrid, Spain
Oruka Therapeutics Investigative Site
Madrid, Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.